RTTNews | Dec 31, 2021 10:14AM EST

10:13 Friday, December 31, 2021 (RTTNews.com) - Shares of micro-cap company Nutriband Inc. (NTRB) are surging over 120% on Friday morning after the pharmaceutical company announced that the Korean Intellectual Property Office has fully issued its patent titled "Abuse and Misuse Deterrent Transdermal System" which is related to the company's lead technology AVERSA.

NTRB is currently trading at $8.71, up $4.80 or 122.76%, on the Nasdaq.

The patent underpins 4p Therapeutics' abuse deterrent transdermal system, AVERSA, which uses taste aversion to address the primary routes of abuse for opioid based transdermal patches.

The KIPO issued a prior notice of allowance in December 2020.

Nutriband develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain.

Read the original article on RTTNews ( https://www.rttnews.com/3252200/nutriband-stock-more-than-doubles-on-patent-approval-from-south-korea.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved